Impact of oral early antiviral therapies for mild–moderate COVID-19 in the outpatient’s setting during Omicron era: a pharmacoeconomic analysis DOI Creative Commons
Vincenzo Scaglione,

Samuele Gardin,

Lolita Sasset

et al.

European journal of medical research, Journal Year: 2024, Volume and Issue: 29(1)

Published: Dec. 19, 2024

Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) decreased mortality hospital admissions in high-risk patients with mild to moderate COVID-19. Nevertheless, there is a lack of data about the pharmacoeconomic impact these antivirals Omicron era. We conducted analysis assessing medical costs use compared those occurred people who refused treatment. The study included first 50 vaccinated against SARS-CoV-2 each month experienced COVID-19 were consecutively treated oral at Padua University Hospital between February 1, 2022, June 30, 2022. In addition, all consecutive met criteria for antiviral therapy during this period but opted not receive treatment as control group. two groups terms associated emergency department visits hospitalizations, which identified primary outcomes study. Nine-hundred-sixty-one analysed, mean age was 67.72 ± 15.19 years 49% males. most prevalent comorbidities cardiovascular disease (57%), obesity (18) diabetes mellitus (18%). Two-hundred-fifty-one (26%) MOL (group A), 252/961 NIR B) 458/961 (48%) C). While generally more favourable observed early group, no statistically significance differences hospitalization or found group A C B C. Total direct significantly higher both comparing (671.42 460€) vs. (1008.42 1562€) (446.58 4977€). main cost driver increased therapy. average 19,334.3 27,030€ C, 8956.2 7412€ 10,267.2€ A. context variant pandemic, agents individuals be expensive avoid treatment, primarily due high it. To enhance efficiency resource allocation, it essential pursue policies aimed reducing drug costs, along conducting further pharmaco-economic studies.

Language: Английский

Update on Early Combination Therapy with Lastest Monoclonal Antibodies and Antivirals as HIV, HCV, Influenza in Extremely Vulnerable Persons with Sars-Cov-2: A Literature Review and Clinical Experience DOI Open Access

Weimer LE

Journal of Clinical Medical Research, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 28

Published: Jan. 31, 2025

The emergence of new variants concern in immunocompromised persons with SARS-CoV-2, particularly those mutations the spike protein, has complicated treatment strategies. Some Therapies focused only on viral clearance effects and not major clinical outcomes. As virus continues to evolve, development broad-spectrum therapies, along personalized approaches treatment, will be crucial managing COVID-19 . After first year period which several treatments were employed early intervention strategies, including use antiretrovirals monoclonal antibodies, have emerged as promising mitigate severity fragile individuals prevent disease progression, hospitalization death even recent time less aggressive SARS-CoV-2 variants. Guidelines, high-quality data for combination exploiting antivirals neutralizing antibodies do exist outpatient setting, especially severe individuals. Nevertheless, studies attempted investigate efect this approach although these are often observational without control groups, generally no adverse reactions from therapy been reported. potential efficacy therapy, based an antiviral plus a antibody, severely patients is matter literature debate scientific word. To date, information concerning using combined therapies limited. In Literature Review we explain Last variant updates vulnerable Sars-Cov-2.

Language: Английский

Citations

0
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis DOI Creative Commons

Giacomo Berti,

Daniele Mengato, Honoria Ocagli

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 16, 2025

Introduction Remdesivir (RDV) and nirmatrelvir/ritonavir (NRM/RTV) are two antiviral agents for treating outpatient adults with mild to moderate symptomatic COVID-19 at high risk of developing a severe disease. The review objectives compare the efficacy safety these antivirals based on published RCT real-world data, evaluate costs from healthcare perspective. Methods This study provides network meta-analysis RDV NRM/RTV early treatment COVID-19. outcomes analysed were hospitalisation any cause serious adverse events. A cost-analysis was performed incorporating drug costs, administration, hospitalisations, management budget impact analysis estimated University Hospital Padua. Results Our results indicated that showed trend towards lower compared (RR 1.59, 95% CI: 0.60–4.20), though this not statistically significant. For safety, demonstrated slightly events 0.92, 0.31–2.74), but without statistical significance. cost could save €550,854.46 per 1,000 patients. Finally, data Padua annual savings €210,977.25 if all treatments administered instead RDV. Discussion comparison therapies did yield significant differences in potential prevent or However, saving favour NRM/RTV.

Language: Английский

Citations

0
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study DOI Creative Commons
Ivan Gentile, Giulio Viceconte,

F. M. Cuccurullo

et al.

Annals of Medicine, Journal Year: 2024, Volume and Issue: 57(1)

Published: Dec. 11, 2024

Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19. Data on the early combined use antivirals and monoclonal antibodies in this population scarce.

Language: Английский

Citations

2
Impact of oral early antiviral therapies for mild–moderate COVID-19 in the outpatient’s setting during Omicron era: a pharmacoeconomic analysis DOI Creative Commons
Vincenzo Scaglione,

Samuele Gardin,

Lolita Sasset

et al.

European journal of medical research, Journal Year: 2024, Volume and Issue: 29(1)

Published: Dec. 19, 2024

Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) decreased mortality hospital admissions in high-risk patients with mild to moderate COVID-19. Nevertheless, there is a lack of data about the pharmacoeconomic impact these antivirals Omicron era. We conducted analysis assessing medical costs use compared those occurred people who refused treatment. The study included first 50 vaccinated against SARS-CoV-2 each month experienced COVID-19 were consecutively treated oral at Padua University Hospital between February 1, 2022, June 30, 2022. In addition, all consecutive met criteria for antiviral therapy during this period but opted not receive treatment as control group. two groups terms associated emergency department visits hospitalizations, which identified primary outcomes study. Nine-hundred-sixty-one analysed, mean age was 67.72 ± 15.19 years 49% males. most prevalent comorbidities cardiovascular disease (57%), obesity (18) diabetes mellitus (18%). Two-hundred-fifty-one (26%) MOL (group A), 252/961 NIR B) 458/961 (48%) C). While generally more favourable observed early group, no statistically significance differences hospitalization or found group A C B C. Total direct significantly higher both comparing (671.42 460€) vs. (1008.42 1562€) (446.58 4977€). main cost driver increased therapy. average 19,334.3 27,030€ C, 8956.2 7412€ 10,267.2€ A. context variant pandemic, agents individuals be expensive avoid treatment, primarily due high it. To enhance efficiency resource allocation, it essential pursue policies aimed reducing drug costs, along conducting further pharmaco-economic studies.

Language: Английский

Citations

0